# LumiDerm vs Radiant Point - Quick Reference Guide

## üîÑ KEY CASE DIFFERENCES

| Parameter | Radiant Point | LumiDerm | Change Rationale |
|-----------|---------------|----------|------------------|
| **TTM Revenue** | $7,040,000 | $6,220,000 | Smaller MedSpa scale |
| **TTM Reported EBITDA** | $1,790,900 | $804,400 | Lower baseline margins |
| **TTM Adjusted EBITDA** | $1,902,900 | $948,400 | Different normalization profile |
| **EBITDA Margin** | 27.0% | 15.2% | More typical single-site margins |

## üèóÔ∏è NORMALIZATIONS COMPARISON

| Adjustment | Radiant Point | LumiDerm | Notes |
|------------|---------------|----------|-------|
| **Owner Add-back** | +$120,000 | +$150,000 | Higher owner salary normalization |
| **One-time Items** | +$40,000 (Legal) | +$90,000 (Rebrand) | Q4-2024 rebrand vs Q3-2024 legal |
| **Rent Normalization** | -$48,000 | -$96,000 | Larger below-market lease benefit |
| **Excluded Items** | EMR $80k (Q2-24) | None | Clean TTM window for LumiDerm |

## üí∞ FINANCIAL STRUCTURE UPDATES

| Component | Radiant Point | LumiDerm | Impact |
|-----------|---------------|----------|--------|
| **Net Debt** | $835,000 | $1,250,000 | Higher leverage profile |
| **Entry Debt %** | 72.5% | 75.0% | More aggressive LBO structure |
| **Debt Rate** | 8.5% | 9.0% | Higher cost for smaller deal |
| **Exit Multiple** | 8.0x | 7.5x | Conservative exit assumption |
| **CapEx Rate** | 1.8% | 2.0% | Higher maintenance needs |
| **Cash Sweep** | 80% | 75% | Slightly lower debt paydown |

## üìä WORKING CAPITAL POLICIES

| Metric | Radiant Point | LumiDerm | Reasoning |
|--------|---------------|----------|-----------|
| **A/R Days** | 10 days | 12 days | Slightly longer collection |
| **Inventory Days** | 60 days | 70 days | Higher inventory buffer |
| **A/P Days** | 35 days | 40 days | Better supplier terms |
| **Product COGS %** | 14.5% | 16.5% | Different product mix |
| **Total COGS %** | 22.0% | 28.5% | Higher total cost structure |

## üéØ EPV ASSUMPTIONS COMPARISON

| Parameter | Radiant Point | LumiDerm | Method |
|-----------|---------------|----------|--------|
| **D&A Annual** | $60,000 | $80,000 | Higher depreciation base |
| **Tax Rate** | 25% | 26% | State tax consideration |
| **Reinvestment Rate** | 10% of EBIT | 8% of EBIT | Lower growth investment |
| **WACC** | 12% | 12% | Same cost of capital |

## üìà EXPECTED RETURNS COMPARISON

| Metric | Radiant Point | LumiDerm | Commentary |
|--------|---------------|----------|------------|
| **IRR** | ~33% | ~22% | Lower returns for smaller deal |
| **MOIC** | ~3.4x | ~2.7x | Still attractive multiple |
| **Entry Equity** | $4.4M | $1.9M | Smaller equity check |
| **Exit Equity** | $15.3M | $5.2M | Proportional to size |

## ‚úÖ VALIDATION CHECKPOINTS

### TTM Metrics
```
LumiDerm Revenue: $6,220,000 ‚úì
LumiDerm Reported: $804,400 ‚úì
LumiDerm Adjusted: $948,400 ‚úì
Margin: 15.2% ‚úì
```

### Base Case Valuation (8.0x)
```
Enterprise Value: $7,587,200 ‚úì
Equity to Seller: $6,337,200 ‚úì
EV/Revenue: 1.2x ‚úì
```

### LBO Structure
```
New Debt (75%): $5,690,400 ‚úì
Sponsor Equity: $1,896,800 ‚úì
Debt Rate: 9.0% ‚úì
```

### EPV Analysis
```
EPV Enterprise: $4,776,200 ‚úì
EPV Equity: $3,526,200 ‚úì
EPV Multiple: 5.0x ‚úì
Conservative Floor: 0.6x vs Market ‚úì
```

## üöÄ DEPLOYMENT STATUS

**‚úÖ ALL LUMIDERM REFINEMENTS IMPLEMENTED**
- Mathematical accuracy validated
- UI/UX updates complete
- Case-specific parameters integrated
- Audit-ready quality achieved

*Ready for production deployment and investment committee presentation.* 